Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Oxford Biomedica plc    OXB   GB00BDFBVT43

OXFORD BIOMEDICA PLC

(OXB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 665 GBX
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
OXFORD BIOMEDICA PLC28.22%885
GILEAD SCIENCES, INC.-7.73%75 173
REGENERON PHARMACEUTICALS56.00%61 638
VERTEX PHARMACEUTICALS-5.39%53 956
WUXI APPTEC CO., LTD.64.97%37 810
BEIGENE, LTD.81.76%27 304
GENMAB A/S48.16%22 791
BIONTECH SE144.78%19 752
HUALAN BIOLOGICAL ENGINEERI..95.02%14 110
MYOKARDIA, INC.205.96%11 891
-
ARGENX SE45.96%11 726
SAREPTA THERAPEUTICS, INC.7.42%10 882
NEUROCRINE BIOSCIENCES, INC..-6.09%9 413
MIRATI THERAPEUTICS, INC.52.63%8 760
ASCENDIS PHARMA A/S14.01%8 439
EXELIXIS, INC.24.29%6 767
More Results
Financials
Sales 2020 84,5 M 110 M 110 M
Net income 2020 -3,28 M -4,28 M -4,28 M
Net cash 2020 24,2 M 31,6 M 31,6 M
P/E ratio 2020 -190x
Yield 2020 -
Capitalization 673 M 879 M 878 M
EV / Sales 2020 7,67x
EV / Sales 2021 5,62x
Nbr of Employees 584
Free-Float 83,7%
Upcoming event on OXFORD BIOMEDICA PLC
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes